Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis

Patent metadata

Field	Value
Publication number	US-10328123-B2
Application number	US-201715659570-A
Country	US
Kind code	B2
Filing date	Jul 25, 2017
Priority date	Feb 25, 2015
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

First claim

The invention claimed is:

1. A method for inhibiting atherosclerosis in a patient the method comprising:
providing said patient a RANK agonist being of:
sufficient amount to induce osteoclasts of said patient to produce foxP3+ CD8 T-cells (Tc REG ); and
insufficient amount to activate enough of said osteoclasts to create new bone loss in said patient;

repeating said providing according to a fixed schedule so as to provide said RANK agonist to said patient at pulsed intervals, said patient having as a result of said fixed schedule increased bone mass compared to a patient not on said fixed schedule.

2. The method of claim 1 , wherein said RANK agonist is RANKL.

3. The method of claim 1 , wherein said low dose comprises 0.125 mg/kg RANKL or less.

4. The method of claim 1 , wherein said low dose comprises about 0.125 mg/kg RANKL.

5. The method of claim 1 , wherein said low dose comprises 0.05 mg/kg RANKL or less.

6. The method of claim 1 , wherein said low dose comprises 0.5 mg/kg RANKL or less.

7. The method of claim 1 , wherein the pulsed intervals are about once a month.

Assignees

• St Louis Univ
• Univ Saint Louis

Inventors

• Aurora Rajeev
• Smith Anna
• Baldan Angel

Classifications

• A61K38/177 Primary

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• A61K38/1709 Primary

  from mammals · CPC title